One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-150371
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 8 |
Affiliation: NewYork–Presbyterian Hospital, New York Hospital Queens, Cornell University, Presbyterian Hospital, Argenx (Belgium), Centrum Onkologii, City Of Hope National Medical Center, LMU Klinikum, Princess Margaret Cancer Centre, The University of Texas MD Anderson Cancer Center, Baker Hughes (Canada), University of Pittsburgh, Janssen (United States), Universität Hamburg, University Medical Center Hamburg-Eppendorf, University Hospital Leipzig, University Hospital Ulm, Roswell Park Cancer Institute, University Hospital of Bern, University of Rochester, Instytut Hematologii i Transfuzjologi, Norton Healthcare, Memorial Sloan Kettering Cancer Center, Janssen (United Kingdom), University of Alberta
Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
